NCT00448253View on ClinicalTrials.gov

Safety and Pharmacokinetic Study of Anthrax Immune Globulin Derived From Human Serum

PHASE1CompletedINTERVENTIONAL
Enrollment

92

Participants

Timeline

Start Date

July 31, 2007

Primary Completion Date

August 31, 2008

Study Completion Date

September 30, 2008

Conditions
Symptoms of Inhalational Anthrax
Interventions
BIOLOGICAL

NP-015

"Three Cohorts evaluating three dosage levels: 210, 420 or 840 units TNA, or placebo.~And a Fourth Cohort at 840 units TNA with 2 additional product lots."

Trial Locations (1)

68502

MDS Pharma Services, Lincoln

Sponsors
All Listed Sponsors
collaborator

Department of Health and Human Services

FED

lead

Emergent BioSolutions

INDUSTRY